Search Results for 'progression months'

progression months published presentations and documents on DocSlides.

CUPISCO trial Tania Tillett
CUPISCO trial Tania Tillett
by wilson
Royal United Hospital. CUPSICO. A . PHASE II, RAND...
Module 12:  Gynecologic Cancers
Module 12: Gynecologic Cancers
by broadcastworld
Paula J Anastasia, RN, MN, AOCN. Kathleen Moore, M...
Jon Trent, MD, PhD Professor of Medicine
Jon Trent, MD, PhD Professor of Medicine
by jane-oiler
Sarcoma . Medical Oncology. The University of . M...
A PCP’s Guide to CKD Screening and Delaying Progression
A PCP’s Guide to CKD Screening and Delaying Progression
by luanne-stotts
Learning Objectives. Utilize appropriate screenin...
Molecular Lessons Learnt from Clinical Trials in the Last Decade
Molecular Lessons Learnt from Clinical Trials in the Last Decade
by altigan
Andrew X. Zhu, MD, PhD. Harvard Medical School. Ma...
Median PFS: 2.6 months (95% CI, 1.7-3.5)
Median PFS: 2.6 months (95% CI, 1.7-3.5)
by ceila
Median PFS: 1.4 months (95% CI, 1.2-1.6) . Median ...
Updates on T-cell lymphoma
Updates on T-cell lymphoma
by grace3
Dr. Stefan K. Barta. University of Pennsylvania, U...
Student Progression
Student Progression
by calandra-battersby
John Kirby. Graduate School. Faculty of Medical S...
Progression of romantic relationships/How to avoid falling
Progression of romantic relationships/How to avoid falling
by jane-oiler
Meeting each. First and Third Monday of every mon...
Progression Monitoring
Progression Monitoring
by stefany-barnette
. Director of Postgraduate Studies. School . of...
Targeting EGFR Exon 20 insertions
Targeting EGFR Exon 20 insertions
by unita
Gregory J. Riely. November 2021. What about those ...
Module 6:  Prostate Cancer
Module 6: Prostate Cancer
by payton
Victoria . Sinibaldi. , RN, MS, CS, CANP, BC. Dani...
Improving long-term outcomes in PAH:
Improving long-term outcomes in PAH:
by reese
Time matters!. Janssen-sponsored virtual symposium...
Disease Progression and Pathogenesis in Congenital Myotonic Dystrophy
Disease Progression and Pathogenesis in Congenital Myotonic Dystrophy
by blanko
Nicholas Johnson, MD. Assistant Professor of Neuro...
Please note, these are the actual
Please note, these are the actual
by pinperc
video-recorded proceedings from the . live CME eve...
Nouveautés dans le CBNPC métastatique
Nouveautés dans le CBNPC métastatique
by vizettan
Celine Mascaux, MD, . PhD. Multidisciplinary . Onc...
Endocrine  resistance: molecular pathways and rational development of targeted therapies
Endocrine resistance: molecular pathways and rational development of targeted therapies
by spottletoefacebook
Grazia Arpino. UniversitĂ  di Napoli Federico II. ...
Managing Advanced Renal Cell
Managing Advanced Renal Cell
by debby-jeon
Carcinoma: Balancing . Efficacy with Quality of L...
BELLE-3: A Phase III Study of
BELLE-3: A Phase III Study of
by faustina-dinatale
Buparlisib. and . Fulvestrant. in Postmenopausa...
FREEDOMS II TRIAL
FREEDOMS II TRIAL
by lois-ondreau
Study Design. 24-month, RCT of . fingolimod. 0.5...
Recurrent Follicular Lymphoma
Recurrent Follicular Lymphoma
by sherrill-nordquist
With a Short First Remission:. How Aggressive Sho...
ASCO 2010:
ASCO 2010:
by phoebe-click
. Highlights from the Annual Clinical Meeting. G...